ClinicalTrials.gg
CompletedNCT01780935OCTAVEUpdated Aug 14, 2017Results posted

Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration

A Phase 3 interventional study of Ranibizumab in Neovascular Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 92 sites in 24 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-08-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
671
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
10th of 124
671 · median 64
Started
2013
with 8 others
Phase 3
31 of 125
2 open now
Registered
74th of 125
by date
Lead sponsor
15 of 125
Novartis Pharmaceuticals

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 10th largest by enrollment of the 124 interventional ones that give a count, is one of 9 that started in 2013, is one of 31 in phase 3, and was the 74th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

This study will evaluate and compare two individualized ranibizumab treatment regimens in patients with neovascular (wet) AMD aiming to achieve and to maintain a maximum visual function benefit, while aiming to avoid unnecessary intravitreal injections.

The results will be used to generate further recommendations on functional and anatomical monitoring of the disease and timing of treatment administration for patients with neovascular AMD. In this context, the study will investigate the utility of optical coherence tomography (OCT) to aid retreatment decisions with ranibizumab.

Read the detailed description

During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Visual impairment predominantly due to neovascular age-related macular degeneration AMD
  • Active, newly diagnosed, untreated CNV due to AMD
  • CNV involving the center of the retina
  • A qualifying vision score at study entry

Exclusion criteria

Exclusion Criteria:

  • Stroke or myocardial infarction less than 3 Months prior to study entry
  • Active injection or inflammation of either eye at the time of study entry
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
671 participants (actual)

Study arms

  • Experimental
    RBZ 0.5 mg: VA only (Group I)

    RBZ 0.5 mg: Visual Acuity (VA) only (Group I) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA) loss due to neovascular (wet) age-related macular degeneration (nAMD)

    Drug: Ranibizumab

  • Experimental
    RBZ 0.5 mg: VA and/or OCT (Group II)

    RBZ 0.5 mg: VA and/or OCT (Group II) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA)loss due to neovascular (wet) age-related macular degeneration (nAMD) and/or signs of wet AMD disease activity on optical coherence tomography (OCT).

    Drug: Ranibizumab

Interventions

  • Intravitreal injections of 0.5 mg Ranibizumab

06

What researchers measure

Primary outcomes

  1. Average Best-corrected Visual Acuity (BCVA) (Letters) Change up to Month 12

    Visual acuity (VA) was assessed during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like VA testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the Visual Acuity averaged up to Month 12 Level of VA (Letters) of the Study Eye.

    Time frame: up to Month 12

Secondary outcomes

  1. Change From Baseline in Visual Acuity (Letters) of the Study Eye up to Month 12

    Visual acuity (VA) was assessed using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like VA testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the Visual Acuity averaged from Baseline to Month 12 Level of VA (Letters) of the Study Eye.

    Time frame: up to Month 12

  2. Gain of Equal or More Than 1, 5, 10, or 15 Letters in Visual Acuity of the Study Eye From Baseline, at Month 12 and 24

    During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

    Time frame: Baseline to Month 12 and 24

  3. Loss of Less Than 5, 10, and 15 Letters in Visual Acuity in the Study Eye From Baseline, at Month 12 and 24

    During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

    Time frame: Baseline to Month 12 and 24

  4. Visual Acuity of 73 Letters or More in the Study Eye at Month 12 and 24

    During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

    Time frame: Month 12 and 24

  5. Average Visual Acuity Change From Month 3 to Month 4 Through Month 24 in the Study Eye

    During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

    Time frame: Month 3 to Month 24

  6. Average Visual Acuity Change From Baseline to Month 1 Through Month 12 and 24 in the Study Eye

    During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

    Time frame: Baseline to Month 12 and 24

  7. Change From Baseline in Central Sub-Field Thickness (CSFT) and Central Sub-Field Volume (CSFV) of the Study Eye Over Time

    During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

    Time frame: Baseline to Month 12 and 24

  8. Dry Retina in the Study Eye on OCT at Month 12 and 24

    During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

    Time frame: Month 12 and 24

  9. Change From Baseline in Lesion Size and Morphology Based on Fluorescein Angiography at Month 12 and 24

    During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

    Time frame: Baseline to Month 12 and 24

  10. Treatment Patterns Over Time in Both Treatment Arms

    During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

    Time frame: Baseline to Month 12 and 24

  11. Change From Baseline in the National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) Scores Over Time

    During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

    Time frame: Baseline to Month 12 and 24

  12. Frequency and Severity of Ocular and Non-ocular Adverse Events Over Time

    During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

    Time frame: Screening to Month 12 and 24

07

Results

Posted Jan 2, 2017
Limitations and caveats
Use of optical coherence tomography guided therapy in the treatment of neovascular age related macular degeneration became standard of care by HA \& Ophth. community during the time this trial was conducted.Novartis terminated this trial.

Participant flow

Participant flow — Overall Study
MilestoneRBZ 0.5 mg: VA Only (Group I)RBZ 0.5 mg: VA and/or OCT (Group II)
Started335336
Safety set334336
Completed00
Not completed335336
Withdrew: Admin problems due to early termination321309
Withdrew: Adverse event24
Withdrew: Death16
Withdrew: Lost to follow-up26
Withdrew: Physician decision11
Withdrew: Protocol deviation01
Withdrew: Patient withdrew consent89

Outcome measures

PrimaryAverage Best-corrected Visual Acuity (BCVA) (Letters) Change up to Month 12

Visual acuity (VA) was assessed during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like VA testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the Visual Acuity averaged up to Month 12 Level of VA (Letters) of the Study Eye.

Time frame:
up to Month 12
Reported as:
Mean · Letters correctly read
Average Best-corrected Visual Acuity (BCVA) (Letters) Change up to Month 12
Letters correctly readRBZ 0.5 mg: VA Only (Group I)RBZ 0.5 mg: VA and/or OCT (Group II)
Average Best-corrected Visual Acuity (BCVA) (Letters) Change up to Month 120.1 ± 6.791.0 ± 7.25
SecondaryChange From Baseline in Visual Acuity (Letters) of the Study Eye up to Month 12

Visual acuity (VA) was assessed using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like VA testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the Visual Acuity averaged from Baseline to Month 12 Level of VA (Letters) of the Study Eye.

Time frame:
up to Month 12
Reported as:
Mean · letters correctly read
Change From Baseline in Visual Acuity (Letters) of the Study Eye up to Month 12
letters correctly readRBZ 0.5 mg: VA Only (Group I)RBZ 0.5 mg: VA and/or OCT (Group II)
Change From Baseline in Visual Acuity (Letters) of the Study Eye up to Month 126.7 ± 13.488.3 ± 13.53
SecondaryGain of Equal or More Than 1, 5, 10, or 15 Letters in Visual Acuity of the Study Eye From Baseline, at Month 12 and 24

During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

Time frame:
Baseline to Month 12 and 24

No measurements were reported for this outcome.

SecondaryLoss of Less Than 5, 10, and 15 Letters in Visual Acuity in the Study Eye From Baseline, at Month 12 and 24

During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

Time frame:
Baseline to Month 12 and 24

No measurements were reported for this outcome.

SecondaryVisual Acuity of 73 Letters or More in the Study Eye at Month 12 and 24

During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

Time frame:
Month 12 and 24

No measurements were reported for this outcome.

SecondaryAverage Visual Acuity Change From Month 3 to Month 4 Through Month 24 in the Study Eye

During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

Time frame:
Month 3 to Month 24

No measurements were reported for this outcome.

SecondaryAverage Visual Acuity Change From Baseline to Month 1 Through Month 12 and 24 in the Study Eye

During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

Time frame:
Baseline to Month 12 and 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in Central Sub-Field Thickness (CSFT) and Central Sub-Field Volume (CSFV) of the Study Eye Over Time

During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

Time frame:
Baseline to Month 12 and 24

No measurements were reported for this outcome.

SecondaryDry Retina in the Study Eye on OCT at Month 12 and 24

During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

Time frame:
Month 12 and 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in Lesion Size and Morphology Based on Fluorescein Angiography at Month 12 and 24

During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

Time frame:
Baseline to Month 12 and 24

No measurements were reported for this outcome.

SecondaryTreatment Patterns Over Time in Both Treatment Arms

During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

Time frame:
Baseline to Month 12 and 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in the National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) Scores Over Time

During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

Time frame:
Baseline to Month 12 and 24

No measurements were reported for this outcome.

SecondaryFrequency and Severity of Ocular and Non-ocular Adverse Events Over Time

During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.

Time frame:
Screening to Month 12 and 24

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RBZ 0.5 mg: VA Only (Group I)—30/334 (9%)111/334 (33.2%)
RBZ 0.5 mg: VA and/or OCT (Group II)—45/336 (13.4%)105/336 (31.3%)
Most frequent serious events
Showing 10 of 93
Most frequent serious events
EventRBZ 0.5 mg: VA Only (Group I)RBZ 0.5 mg: VA and/or OCT (Group II)
Femoral neck fractureInjury, poisoning and procedural complications1/3344/336
Atrial fibrillationCardiac disorders0/3343/336
PneumoniaInfections and infestations0/3343/336
OsteoarthritisMusculoskeletal and connective tissue disorders2/3341/336
SyncopeNervous system disorders2/3340/336
Lower respiratory tract infectionInfections and infestations1/3342/336
Ovarian cystReproductive system and breast disorders0/3342/336
HypertensionVascular disorders0/3342/336
LymphadenopathyBlood and lymphatic system disorders1/3340/336
Cardiopulmonary failureCardiac disorders1/3340/336
Most frequent other events
Showing 10 of 16
Most frequent other events
EventRBZ 0.5 mg: VA Only (Group I)RBZ 0.5 mg: VA and/or OCT (Group II)
NasopharyngitisInfections and infestations24/33411/336
Intraocular pressure increased (Study eye)Investigations12/33421/336
Conjunctival haemorrhage (Study eye)Eye disorders19/33410/336
HypertensionVascular disorders18/33415/336
InfluenzaInfections and infestations15/33415/336
Dry eye (Study eye)Eye disorders10/3347/336
Eye pain (Study eye)Eye disorders10/3349/336
Back painMusculoskeletal and connective tissue disorders4/33410/336
Vitreous floaters (Study eye)Eye disorders6/3348/336
Dry eye (Fellow untreated eye)Eye disorders7/3344/336

Baseline characteristics

Age, Continuous
Age, Continuous(years)RBZ 0.5 mg: VA Only (Group I)RBZ 0.5 mg: VA and/or OCT (Group II)Total
Mean73.9 ± 7.8675.3 ± 7.9174.6 ± 7.91
Sex: Female, Male
Sex: Female, Male(Participants)RBZ 0.5 mg: VA Only (Group I)RBZ 0.5 mg: VA and/or OCT (Group II)Total
Female213194407
Male122142264
08

Study locations

92 sites
  • Novartis Investigative Site
    Buenos Aires, C1122AAI, Argentina
  • Novartis Investigative Site
    Ciudad Autonoma de Bs As, C1015ABO, Argentina
  • Novartis Investigative Site
    Wien, 1090, Austria
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 3N9, Canada
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 2E1, Canada
  • Novartis Investigative Site
    London, Ontario N6A 4G5, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1H 8L6, Canada
  • Novartis Investigative Site
    Boisbriand, Quebec J7H 1S6, Canada
  • Novartis Investigative Site
    Sherbrooke, Quebec J1J 2B8, Canada
  • Novartis Investigative Site
    Medellin, Antioquia 001, Colombia
  • Novartis Investigative Site
    Bogotá, Cundinamarca 7550000, Colombia
  • Novartis Investigative Site
    Olomouc, CZE 775 20, Czechia
  • Novartis Investigative Site
    Brno, 625 00, Czechia
  • Novartis Investigative Site
    Hradec Kralove, 505 05, Czechia
  • Novartis Investigative Site
    Praha 10, 100 34, Czechia
  • Novartis Investigative Site
    HUS, 00029, Finland
  • Novartis Investigative Site
    Kuopio, 70211, Finland
  • Novartis Investigative Site
    Paris, 75015, France
  • Novartis Investigative Site
    Bonn, 53127, Germany
  • Novartis Investigative Site
    Chemnitz, 09113, Germany
  • Novartis Investigative Site
    Darmstadt, 64297, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Koeln, 50924, Germany
  • Novartis Investigative Site
    Muenster, 48145, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    München, 80336, Germany
  • Novartis Investigative Site
    Regensburg, 93053, Germany
  • Novartis Investigative Site
    Ampelokipi, Athens 11 526, Greece
  • Novartis Investigative Site
    Glyfada, Athens 16675, Greece
  • Novartis Investigative Site
    Athens, GR 156 69, Greece
  • Novartis Investigative Site
    Ioannina, 45500, Greece
  • Novartis Investigative Site
    Guatemala City, 01009, Guatemala
  • Novartis Investigative Site
    Guatemala City, 01010, Guatemala
  • Novartis Investigative Site
    Budapest, 1076, Hungary
  • Novartis Investigative Site
    Budapest, 1083, Hungary
  • Novartis Investigative Site
    Budapest, 1106, Hungary
  • Novartis Investigative Site
    Budapest, 1133, Hungary
  • Novartis Investigative Site
    Budapest, 1145, Hungary
  • Novartis Investigative Site
    Debrecen, 4012, Hungary
  • Novartis Investigative Site
    Szeged, H-6725, Hungary
  • Novartis Investigative Site
    Veszprem, H-8200, Hungary
  • Novartis Investigative Site
    Zalaegerszeg, 8900, Hungary
  • Novartis Investigative Site
    Dublin, Ireland
  • Novartis Investigative Site
    Waterford, Ireland
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Milano, MI 20100, Italy
  • Novartis Investigative Site
    Milano, MI 20132, Italy
  • Novartis Investigative Site
    Udine, UD 33100, Italy
  • Novartis Investigative Site
    Kaunas, LTU 50009, Lithuania
  • Novartis Investigative Site
    Vilnius, LT-08661, Lithuania
  • Novartis Investigative Site
    Ciudad De Mexico, Distrito Federal 06800, Mexico
  • Novartis Investigative Site
    Den Bosch, 5223 GZ, Netherlands
  • Novartis Investigative Site
    Nijmegen, 6525 EX, Netherlands
  • Novartis Investigative Site
    Rotterdam, 3011 BH, Netherlands
  • Novartis Investigative Site
    Panama City, 0819-12316, Panama
  • Novartis Investigative Site
    Coimbra, 3000-354, Portugal
  • Novartis Investigative Site
    Lisboa, 1050-085, Portugal
  • Novartis Investigative Site
    Porto, 4200-319, Portugal
  • Novartis Investigative Site
    Bratislava, 82606, Slovakia
  • Novartis Investigative Site
    Bratislava, 85107, Slovakia
  • Novartis Investigative Site
    Nitra, 94901, Slovakia
  • Novartis Investigative Site
    Trencin, 91171, Slovakia
  • Novartis Investigative Site
    Zilina, 01207, Slovakia
  • Novartis Investigative Site
    Zvolen, 960 01, Slovakia
  • Novartis Investigative Site
    Oviedo, Asturias 33012, Spain
  • Novartis Investigative Site
    Santiago de Compostela, Galicia 15706, Spain
  • Novartis Investigative Site
    Bilbao, Pais Vasco 48006, Spain
  • Novartis Investigative Site
    Barcelona, 08025, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
  • Novartis Investigative Site
    Linköping, SE-581 85, Sweden
  • Novartis Investigative Site
    Bern, 3012, Switzerland
  • Novartis Investigative Site
    Genève, 1204, Switzerland
  • Novartis Investigative Site
    Lausanne, 1007, Switzerland
  • Novartis Investigative Site
    Zuerich, 8063, Switzerland
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Ankara, 06490, Turkey
  • Novartis Investigative Site
    Frimley, Surrey GU16 7UJ, United Kingdom
  • Novartis Investigative Site
    Belfast, BT12 6BA, United Kingdom
  • Novartis Investigative Site
    Bristol, BS1 2LX, United Kingdom
  • Novartis Investigative Site
    Cheshire, CW14QJ, United Kingdom
  • Novartis Investigative Site
    Derby, DE22 3NE, United Kingdom
  • Novartis Investigative Site
    Gloucester, GL1 3NN, United Kingdom
  • Novartis Investigative Site
    Great Yarmouth, NR31 6LA, United Kingdom
  • Novartis Investigative Site
    Guildford, Surrey, GU2 5XX, United Kingdom
  • Novartis Investigative Site
    Hull, HU3 2JZ, United Kingdom
  • Novartis Investigative Site
    London, EC1V 2PD, United Kingdom
  • Novartis Investigative Site
    London, SE5 9RS, United Kingdom
  • Novartis Investigative Site
    Middlesborough, TS4 3BW, United Kingdom
  • Novartis Investigative Site
    Rugby, CV22 5PX, United Kingdom
  • Novartis Investigative Site
    Southampton, SO16 6YD, United Kingdom
  • Novartis Investigative Site
    Wolverhampton, WV10 0QP, United Kingdom
  • Novartis Investigative Site
    York, YO31 8HE, United Kingdom
09

References and documents

Publications

  • Staurenghi G, Garweg JG, Gerendas BS, Macfadden W, Gekkiev B, Margaron P, Dunger-Baldauf C, Kolar P. Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration - results from the randomized, phase IIIb OCTAVE study. BMC Ophthalmol. 2020 Jan 9;20(1):18. doi: 10.1186/s12886-019-1251-6. PubMed 31918685 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Jul 2015, 25 months.

Results were first posted in Jan 2017, 1 year 5 months after primary completion.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 25 months is close to that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2013
First posted
Jan 31, 2013
StartActual
Jun 3, 2013
Primary completionActual
Jul 9, 2015
CompletionActual
Jul 9, 2015
Results first posted
Jan 2, 2017
Last update
Aug 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01780935
Responsible party
Sponsor
First posted
Jan 31, 2013
Start date
Jun 3, 2013
Primary completion
Jul 9, 2015
Completion
Jul 9, 2015
Results posted
Jan 2, 2017
Last update
Aug 14, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion